Results from the SYNERGY and A to Z trials have shown Aventis’ [AVE] Lovenox (enoxaparin) fails to offer significant clinical benefit over unfractionated heparin (UFH) in acute coronary syndrome (ACS) patients. Physicians will have to consider whether the convenient delivery of enoxaparin will be enough to justify its continued usage over UFH, given the significant cost difference.
